Alex Therapeutics is a Stockholm-based Medtech startup that develops digital therapies and therapeutic apps (DTx). We create and deliver accessible, evidence-based treatments for mental health and addiction through smartphone apps. By combining AI with evidence-based psychology, we deliver digital medicine apps to undertreated patients around the world. Our mission is to support people living with complex conditions like rare diseases and cancer by providing practical and emotional support through clinically validated digital tools.

Founded in 2018 by psychologist John Drakenberg and theoretical computational molecular biophysicist Oliver Fleetwood, Alex Therapeutics integrates psychology, design, and technology to personalize healthcare and improve quality of life. The company specializes in oncology and rare diseases, addressing complex treatment regimes and emotional distress. With a growing team of 20+ experts across the EU and US, Alex Therapeutics leads digital innovation by leveraging AI and machine learning to enhance user experience and patient outcomes. The company is a trusted digital health partner for pharma and pioneers in Software as a Medical Device (SaMD) digital therapeutics.

Headquarters: Stockholm, Stockholm County
Founded: 2018
Company Size: About 20 employees
Industry: Technology, Information and Internet
Specialties: Digital Health, SaMD, MedTech, Rare Diseases, Oncology, PDURS, Companion App